9.37
Schlusskurs vom Vortag:
$9.44
Offen:
$9.38
24-Stunden-Volumen:
33,431
Relative Volume:
0.07
Marktkapitalisierung:
$1.43B
Einnahmen:
$43.34M
Nettoeinkommen (Verlust:
$-247.99M
KGV:
-4.7472
EPS:
-1.9738
Netto-Cashflow:
$-224.28M
1W Leistung:
-1.66%
1M Leistung:
-3.19%
6M Leistung:
-6.57%
1J Leistung:
+61.36%
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
IMTX
Immatics N V
|
9.37 | 1.44B | 43.34M | -247.99M | -224.28M | -1.9738 |
|
VRTX
Vertex Pharmaceuticals Inc
|
521.93 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
802.00 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,002.66 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
138.46 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
209.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-05-28 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2020-11-20 | Eingeleitet | BofA Securities | Buy |
| 2020-09-22 | Eingeleitet | Goldman | Buy |
| 2020-07-27 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immatics N V Aktie (IMTX) Neueste Nachrichten
Price-Driven Insight from (IMTX) for Rule-Based Strategy - Stock Traders Daily
Immatics N.V. (IMTX) Holds at $9.43 as Shares Consolidate Above Key SupportShort Term Trading Ideas - vinanet.vn
Immatics stock holds near USD 9.60 after market cap update - AD HOC NEWS
Immatics N.V. Warrants (IMTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Immatics (NASDAQ:IMTX) Shares Up 5.3% on Insider Buying Activity - MarketBeat
Insider Buying: Immatics (NASDAQ:IMTX) Director Purchases 863,060 Shares of Stock - MarketBeat
Perceptive fund boosts Immatics (IMTX) stake with new open-market share buy - Stock Titan
Perceptive Advisors Acquires 863,060 Shares of Immatics N.V. at $8.69 Each - Kalkine Media
Immatics (NASDAQ: IMTX) raises fresh cash to fund oncology pipeline - Stock Titan
Form 424B2 Immatics N.V. - StreetInsider
Why is Immatics stock climbing today? By Investing.com - Investing.com India
Immatics downgraded to Buy due to partnership c... - Pluang
Why Immatics (IMTX) Is Down 5.4% After Mixed First‑Half 2026 Loss Trends And What's Next - simplywall.st
Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
James Nelson Pepin Net Worth (2026) - GuruFocus
Immatics (NASDAQ:IMTX) Shares Down 8%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Immatics Announces Second Quarter 2026 Financial Results and Business Update - Sahm
Immatics (IMTX) awards counsel Nelson 225K share package - Stock Titan
Immatics Releases Q2 2026 Financial Results - AlphaStreet
Immatics Q2 revenue rises to $10.4 million - grafa.com
Immatics earnings on deck as analysts eye revenue trajectory By Investing.com - Investing.com India
Immatics earnings on deck as analysts eye revenue trajectory - Investing.com
Immatics Q2 Results: EPS misses estimate, sales up 93% YoY - scanx.trade
IMTX Looks 176.9% Overvalued on GF Value™ - GuruFocus
Immatics (NASDAQ:IMTX) Issues Earnings Results - MarketBeat
Immatics (IMTX) Slides 2.01% as Shares Approach Key $8.79 Support LevelQuality Factor - Vinanet
Immatics Posts Interim Q2 2026 Results and Updates Investor Materials - TipRanks
Immatics' Q2 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Revenue 9.1M Euros, vs. FactSet Est of 10.4M Euros - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.46 Euros a Share, vs. FactSet Est of 0.45 Euros Loss - marketscreener.com
Immatics reports Q2 EPS (46c), consensus (48c) - TipRanks
Immatics: Q2 Earnings Snapshot - marketscreener.com
Immatics (NASDAQ: IMTX) posts €120m loss funding Phase 3 melanoma push - Stock Titan
Immatics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update - Moomoo
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentEPS Surprise History - vinanet.vn
Immatics (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Preclinical and Clinical InvestmentConsensus Beat Rate - dars.gov.et
Immatics (IMTX): Baker Bros. group reports 9.5M-share, 7% ownership stake - Stock Titan
Genetically Reprogrammed T Cells Erase Terminal Kidney Cancer in Teen, NEJM Reports - techtimes.com
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immatics N.V. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Immatics N.V. (IMTX) Stock Analysis: Unveiling An 89.67% Potential Upside For Investors - DirectorsTalk Interviews
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D-Driven BurnDividend Cut Risk - vinanet.vn
How Immatics N.v. (IMTX) Affects Rotational Strategy Timing - Stock Traders Daily
Immatics (IMTX): Will Anzu-cel Take The PRAME Crown In Advanced Melanoma? - RTTNews
Immatics (IMTX) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Immatics (IMTX) Slips 5.9% to $8.66 as Biotech Selling Pressure IntensifiesForce Index - dars.gov.et
Immatics N.V. (IMTX) Stock Analysis: Exploring a 105% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
IMTX|Immatics NV|Price:9.425|Chg%:-0.165 - TradingKey
Immatics Q1 2026 Earnings: EPS Misses Estimates as Pipeline Advances Offset Financial HeadwindsEarnings Trend Analysis - vinanet.vn
Finanzdaten der Immatics N V-Aktie (IMTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):